Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

Helsinn, BridgeBio Pharma Amend Infigratinib Pact For Oncology Indications

Helsinn Group and BridgeBio Pharma Inc (NASDAQ:BBIO) have updated their existing strategic collaboration to develop, manufacture, and commercialize infigratinib for oncology indications.

  • Under the amended and restated agreement terms, Helsinn will gain an exclusive license to commercialize infigratinib in the U.S.
  • Helsinn will be responsible for developing, manufacturing, and commercializing infigratinib in oncology indications except for achondroplasia or any other skeletal dysplasias except in mainland China, Hong Kong, and Macau. 
  • Also See: Why BridgeBio Pharma Shares Are Plummeting Today?
  • BridgeBio will be eligible to receive regulatory and commercial milestone payments and tiered royalties on adjusted net sales from Helsinn. 
  • BridgeBio will retain all rights to develop, manufacture and commercialize infigratinib in skeletal dysplasia, including achondroplasia.
  • Price Action: BBIO shares are down 1.21% at $8.16 during the market session on the last check Thursday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.